Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | CASP1 | P29466 | 1/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023243 | 1.00 | MAPT (1.00) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL13836369 | 0.93 | MAPT (0.87) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL31023222 | 0.93 | MAPT (0.87) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL13836495 | 0.93 | MAPT (0.87) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL2153135 | 0.92 | MAPT (0.85) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL2153056 | 0.91 | MAPT (0.83) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL31023288 | 0.91 | MAPT (0.83) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL6721108 | 0.91 | MAPT (0.83) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL2153383 | 0.91 | MAPT (0.83) | MAPTTP53KDM4ELMNAHTT | |
| SCHEMBL15783216 | 0.90 | MAPT (0.82) | MAPTTP53KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079697-B1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY | UNIV CORNELL (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | CORNELL UNIVERSITY (US) | 2020-11-19 | — | — | US | disclosed |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20160317526-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | CORNELL UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015089416-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY | CORNELL UNIVERSITY (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | ATF4, P4HTM, P4HA1 | MAPT 1958/4885TP53 2913/4885KDM4E 1440/4885 |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | MAPT 4328/4885TP53 3840/4885KDM4E 4113/4885 |
| US-20160317526-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | HIF1AN, EGLN3, EGLN2 | MAPT 2108/4885TP53 2633/4885KDM4E 1623/4885 |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | HIF1AN, EGLN3, EGLN2 | MAPT 2108/4885TP53 2633/4885KDM4E 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.